Comparison Of Clinical Efficacy Of Combination Gemcitabine With Tegaserod Versus Gemcitabine With Capecitabine For The Treatment Of Advanced Pancreatic Cancer

Digestive system due to long-term is in working status,its damage degree higher compared with other systems,and in the digestive system and pancreatic cancer is one of the most common disease,the symptoms and because of its low predictability and long incubation period,fast deterioration and so on characteristics for healing difficulty of high malignant tumor.In recent years,the incidence and death rate of pancreatic cancer have increased significantly in China.According to the survey data show that in 2011 the United States disease,pancreatic cancer in the arrangement of all kinds of disease cancer has risen to the tenth,respectively in the probability of onset to death in both men and women to rise to the fourth and the third.Pancreatic cancer is characterized by its largest foresight is very low,due to its clinical symptoms are not obvious,the early check unable to find out its prevalence,and when its development to late to check out the corresponding clinical symptoms,so the cure rate is extremely low.In the current treatment of pancreatic cancer is the most effective way is to use surgery to tumor resection,but with tumor spread speed and not removed completely,so even did a surgical excision of the tumor,but very low risk of patients were fully recovered,it was also because began to study the situation of the current medical use radiation ways to control the development and progression of disease.Objective:Clinical analysis of the treatment of pancreatic cancer and the efficacy of gemcitabine plus S-1 or gemcitabine plus Capecitabine chemotherapy.Methods:This study collected CT(ultrasound)guided fine needle aspiration or laparotomy to take tissue disease diagnosed late pancreatic cancer patients 60 cases.Patients were divided into gemcitabine plus tegaserod and gemcitabine plus capecitabine,according to the chemotherapy regimen used.The patient’s general condition and adverse reaction data before treatment were collected.The curative effect was evaluated according to the evaluation method of RECIST.And analyzed by spss18.0 software.The comparison of measurement data among multiple groups was analyzed by one-way ANOVA.The data of count among groups were compared by chi-square test.P<0.05 was considered as statistically significant.Results:1.Both groups had good control effects before treatment.2.The control rate of the disease control group was 60%and 56.67%respectively,compared with the disease control rate,which was not statistically significant.The quality of life improvement was 67.7%and 76.6%.The differences between groups were not statistically significant.3.The incidence of sibling syndrome was lower than that of GX chemotherapy group(13.33%、36.67%,χ~2=4.356,P=0.037).Conclusion:There is no significant difference between the two groups in the treatment of pancreatic cancer with the combination chemotherapy of tigio and capecitabine,and can be used according to the patient’s adverse reaction and physical condition.